Progenics Falls After Two Deaths in Cancer Drug Trial
This article is for subscribers only.
Progenics Pharmaceuticals Inc. fell the most in 18 months after a study summary showed two patients died of sepsis in a trial of the company’s experimental prostate cancer treatment.
Progenics tumbled 27 percent to $4.50 at the close in New York, the biggest intraday drop since July 30, 2012. The Tarrytown, New York-based company’s stock has gained 52 percent in the past 12 months.